2026 Q1
SunRay101 antibody screening expected to be completed in Q1 2026.
Smart Health Management:
Smart Health Management:
A Full Life-Cycle Closed Loop from Technology to Service
A Full Life-Cycle Closed Loop from Technology to Service
- The domestic health management market remains fragmented, lacking full-chain, technology-driven service providers.
- Consumers face difficulty accessing one-stop health solutions rooted in cutting-edge biotechnology with traceable outcomes.
SUNRAY Approach
Leveraging our proprietary antibody drugs, cell therapeutics, and regenerative materials developed across five AI platforms, we have built a physical service network covering the entire continuum from precision diagnostics and interventional therapy to rehabilitation and anti-aging care. Currently operational: CoJump Sports Medicine Center (Hangzhou, the province's largest sports rehabilitation facility), Starlight Aesthetics Center (regenerative aesthetics), Aprbio Bio-Medical Care Center (cell-based wellness), and Aprbio Longevity & Anti-Aging Clinic (Jinhua).
Target Population
Post-surgical rehabilitation patients, sports injury population, anti-aging seekers, and individuals with suboptimal health or chronic disease risk.
Service Value
Consumers gain access to a one-stop health management platform where technologies are traceable to their source, protocols are data-driven, and outcomes are fully trackable.
Technology Infrastructure
R&D across all four application domains is supported by the following three technology platforms:
Metabolic Disease Therapeutics
Musculoskeletal Regeneration
Regenerative Biomaterials
Smart Health Management
AI De Novo Antibody Platform
Directly generates antibodies against antigen epitopes, reducing R&D costs by 70%
AI Cell Screening Platform
Tens of millions of data points accumulated; participates in industry standard-setting
AI Biomaterial Composite Design Platform
Multi-physics simulation reduces experimental workload by over 50%
Key Milestones
-
-
2026
China's first tendon stem cell IIT clinical trial was approved at the Second Affiliated Hospital of Zhejiang University.
-
2026 Q2
PLLA microspheres have completed enrollment of 240+ patients (Class III medical device).
-
2026
Longevity Clinic to be established in 2026.
